These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

621 related items for PubMed ID: 24367037

  • 21. New disease-modifying therapies and new challenges for MS.
    Yadav V, Bourdette D.
    Curr Neurol Neurosci Rep; 2012 Oct; 12(5):489-91. PubMed ID: 22760478
    [Abstract] [Full Text] [Related]

  • 22. [Current treatment of multiple sclerosis].
    Csépány T.
    Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
    [Abstract] [Full Text] [Related]

  • 23. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P, Szabo K, Hornberger E, Griebe M, Hennerici MG, Kieseier BC, Gass A.
    J Neuroimaging; 2014 Feb; 24(4):425-8. PubMed ID: 23323645
    [Abstract] [Full Text] [Related]

  • 24. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Muñoz-Culla M, Irizar H, Castillo-Triviño T, Sáenz-Cuesta M, Sepúlveda L, Lopetegi I, López de Munain A, Olascoaga J, Baranzini SE, Otaegui D.
    Mult Scler; 2014 Dec; 20(14):1851-9. PubMed ID: 24852919
    [Abstract] [Full Text] [Related]

  • 25. Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands.
    Heisen M, Treur MJ, van der Hel WS, Frequin ST, Groot MT, Verheggen BG.
    J Med Econ; 2012 Dec; 15(6):1149-58. PubMed ID: 22737996
    [Abstract] [Full Text] [Related]

  • 26. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Peaureaux D, Pignolet B, Biotti D, Bucciarelli F, Gaina J, Bucur C, Clanet M, Martin-Blondel G, Brassat D.
    Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
    [No Abstract] [Full Text] [Related]

  • 27. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
    Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L.
    JAMA Neurol; 2014 Aug; 71(8):954-60. PubMed ID: 24977406
    [Abstract] [Full Text] [Related]

  • 28. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 Aug; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 29. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab.
    Ropper AH.
    N Engl J Med; 2012 May 17; 366(20):1938-9. PubMed ID: 22591300
    [No Abstract] [Full Text] [Related]

  • 30. Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
    Hoepner R, Havla J, Eienbröker C, Tackenberg B, Hellwig K, Meinl I, Hohlfeld R, Gold R, Kümpfel T, Kleiter I.
    Mult Scler; 2014 Nov 17; 20(13):1714-20. PubMed ID: 24842961
    [Abstract] [Full Text] [Related]

  • 31. Natalizumab to fingolimod washout in patients at risk of PML: when good intentions yield bad outcomes.
    Giovannoni G, Naismith RT.
    Neurology; 2014 Apr 08; 82(14):1196-7. PubMed ID: 24610331
    [Abstract] [Full Text] [Related]

  • 32. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
    Castrop F, Kowarik MC, Albrecht H, Krause M, Haslinger B, Zimmer C, Berthele A, Hemmer B.
    Neurology; 2012 Mar 20; 78(12):928-30. PubMed ID: 22402856
    [No Abstract] [Full Text] [Related]

  • 33. Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab.
    Baumgartner A, Stich O, Rauer S.
    Int J Neurosci; 2012 Jan 20; 122(1):35-9. PubMed ID: 21913869
    [Abstract] [Full Text] [Related]

  • 34. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.
    Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P.
    Mult Scler; 2012 Nov 20; 18(11):1640-3. PubMed ID: 23100526
    [Abstract] [Full Text] [Related]

  • 35. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D, Ghezzi A, Annovazzi PO, Colombo B, Martinelli V, Minonzio G, Moiola L, Rodegher M, Zaffaroni M, Comi G.
    Mult Scler; 2016 Sep 20; 22(10):1315-26. PubMed ID: 27230789
    [Abstract] [Full Text] [Related]

  • 36. Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
    Décard BF, Haghikia A, Tönnes C, Thöne J, Lukas C, Chan A, Gold R.
    Mult Scler; 2013 Feb 20; 19(2):249-51. PubMed ID: 22596228
    [Abstract] [Full Text] [Related]

  • 37. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
    O'Day K, Meyer K, Miller RM, Agarwal S, Franklin M.
    J Med Econ; 2011 Feb 20; 14(5):617-27. PubMed ID: 21777161
    [Abstract] [Full Text] [Related]

  • 38. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.
    Carruthers RL, Rotstein DL, Healy BC, Chitnis T, Weiner HL, Buckle GJ.
    Mult Scler; 2014 Sep 20; 20(10):1381-90. PubMed ID: 24852928
    [Abstract] [Full Text] [Related]

  • 39. Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
    Boudot de la Motte M, Louapre C, Bertrand A, Reach P, Lubetzki C, Papeix C, Maillart E.
    Mult Scler; 2017 Apr 20; 23(4):614-616. PubMed ID: 28273764
    [Abstract] [Full Text] [Related]

  • 40. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP.
    BMC Neurol; 2016 Jul 12; 16():98. PubMed ID: 27405225
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.